Back to results
US 2014/0178423 A1Published application
Novel compositions and methods
AssigneeGlaxosmithkline Biologicals SA
InventorsPascal Mettens, James Brown, Dennis Murphy
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
Claims18
A method for the treatment or prevention of latent tuberculosis comprising the administration of a polypeptide
- comprising:
- (i) an Rv3616c protein sequence;
- (ii) a variant of an Rv3616c protein sequence;
- or
- (iii) an immunogenic fragment of an Rv3616c protein sequence;
- to a subject in need thereof, wherein said polypeptide induces an immune response.
3 more elements
A method for the treatment or prevention of latent tuberculosis comprising the administration of a polynucleotide
- comprising a nucleic acid sequence encoding a polypeptide comprising:
- (i) an Rv3616c protein sequence;
- (ii) a variant of an Rv3616c protein sequence;
- or
- (iii) an immunogenic fragment of an Rv3616c protein sequence;
- to a subject in need thereof, wherein said polynucleotide induces an immune response.
3 more elements
Dependencies are inferred from the claim text.